Heparin - Controversies and misconceptions

Cardiovascular Surgery

Volumn 4, Issue 6, 1996, Pages 691-700

  Blaisdell, F W ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Medical Center   (United States)

^c Department of Surgery ^*  (United States)

Author keywords

bleeding; heparin anticoagulation; heparin monitoring

Indexed keywords

HEPARIN; ANTICOAGULANT AGENT; ANTITHROMBIN III;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; HEART FUNCTION; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; CHEMICALLY INDUCED DISORDER; EMBOLISM; METABOLISM; MONITORING; PRACTICE GUIDELINE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

ANTICOAGULANTS; ANTITHROMBIN III; EMBOLISM; HEMORRHAGE; HEPARIN; HUMANS; MONITORING, PHYSIOLOGIC; PLATELET AGGREGATION; PRACTICE GUIDELINES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 0030345654     PISSN: 09672109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-2109(96)00056-7     Document Type: Article

References (104)

1. 1. Baird RJ. The story of heparin - as told by sketches from the lives of William Howell, Jay McLean, Charles Best, and Gordon Murray. J Vasc Surg 1990; 11: 4-18.
2. 2. Majerus PW, Broze GJ Jr, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic and antiplatelet drugs. In: Goodman and Gilman's The Pharmacological Basis sof Therapeutics, 8th ed. New York: Pergamon Press, 1990: 1313-17.
3. 3. Fareed J. Heparin, its fractions, fragments and derivatives. Semin Thromb Hemost 1985; 11: 1-9.
4. 4. Fareed J, Hoppensteadt D, Walenga JM. Low molecular weight heparins in the management of thrombotic disorders. In: Fareed J. ed. Low Molecular Weight Heparin in the Prophylaxis and Treatment of Thrombosis. Chicago: Loyola University Press, 1994: 233-41.
5. 5. Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
6. 6. Barrowcliffe TW. LMWH: relationship between antithrombotic and anticoagulant effects. In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 205-20.
7. 7. Abildgaard U. Tissue factor pathway inhibitor and heparin. In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 199-204.
8. 8. Bick RL. Antithrombotic therapy. In: Bick RL, ed. Hematology: Clinical and Laboratory Practice. St. Louis: Mosby, 1993: 1603-31.
9. 9. Bithell TC. Thrombosis and antithrombotic therapy. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's Clinical Hematology, 9th ed. Philadelphia: Lee and Febiger, 1993: 1515-28.
10. 10. Dietrich W, Spannagl M, Schramm W et al. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: 505-14.
11. 11. Fernandez F, N'guyen P, Van Ryn J, Ofosu FA., Hirsh J, Buchanan MR. Hemorrhagic dose of heparin and other glycosaminoglycans. Thromb Res 1986; 43: 491-5.
12. 12. Zucker MB. Heparin and platelet function. Fed Proc 1977; 36: 47-9.
13. 13. Grulich-Henn J, Preissner KT, Muller-Berghaus G. Heparin stimulates fibrinolysis in mesothelial cells by selective induction of tissue-plasminogen activator but not plasminogen activator inhibitor-1 synthesis. Thromb Haemost 1990; 64: 420-5.
14. 14. Ekre H-P, Naparastek Y, Lider O et al. Anti-inflammatory effects of heparin and its derivatives. Inhibition of complement and of lymphocyte migration. In: Lanc DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 329-40.
15. 15. Saliba MJ, Saliba SJ, Heparin in burns: dose related and dose dependent effects. Thrombosis el Diathesis Haemorrhagica 1974; 33: 113-23.
16. 16. Fiore L, Deykin D. Anticoagulant therapy. In: Beutler E , Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York; McGraw-Hill Inc., 1995: 1562-80.
17. 17. Deykin D. Current concepts: the use of heparin. N Engl J Med 1982; 280: 937-8.
18. 18. Holm HA, Kalvenes S, Abildgaard U. Changes in plasma antithrombin during intravenous heparin therapy. Scand J Haematol 1985; 35: 564-9.
19. 19. Hemker HC, Beguin S. The mode of action of heparins in vitro and in vivo. In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 221-30.
20. 20. Howell WH, Holt E. Two new factors in blood coagulation -heparin and pro-antithrombin. Am J Physiol 1918; 47: 328-41.
21. 21. Best CH. Heparin and thrombosis. J Physiol 1938; 92: 20-31.
22. 22. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation 1959; 19: 79-86.
23. 23. Murray DWG, Jaques LB, Perrett TS, Best CH. Heparin and vascular occlusion. Can Med Assoc J 1936; 35: 621-2.
24. 24. Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937; 79: 407-26.
25. 25. Jorpes JE. Heparin in the Treatment of Thrombosis, 2nd ed. London: Oxford University Press, 1946.
26. 26. Murray DWG, Jaques LB, Perrett TS, Best CH. Heparin and the thrombosis of veins following injury. Surgery 1937; 2: 163-87.
27. 27. Murray GDW. Experimental surgery: heparin in thrombosis and embolism. Br J Surg 1939; 27: 567-98.
28. 28. Murray G. Anticoagulants in venous thrombosis and the prevention of pulmonary embolism. Surg Gynecol Obstet 1947; 84: 665-8.
29. 29. Murray GWD, Best CH. The use of heparin in thrombosis. Ann Surg 1938; 108: 163-77.
30. 30. Murray GWD. Heparin in surgical treatment of blood vessels. Arch Surg 1940; 40: 307-25.
31. 31. Jaques LB, Ricker AG. The relationship between heparin dosage and clotting. Blood 1948; 3: 1197-212.
32. 32. Jaques LB. A fundamental consideration of anticoagulant therapy. N Engl J Med 1950; 243: 395-401.
33. 33. Wessler S. Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments. J Clin Invest 1952; 31: 1011-114.
34. 34. Wessler S. Studies in intravascular coagulation. II. A comparison of the effect of dicoumarol and heparin on clot formation in isolated venous segments. J Clin Invest 1953; 32: 650-3.
35. 35. Wessler S. Studies in intravascular coagulation. III. The pathogenesis of serum-induced venous thrombosis. J Clin Invest 1955; 34: 647-51.
36. 36. Wessler S. Studies in intravascular coagulation. IV. The effect of heparin and dicoumarol on serum-induced venous thrombosis. Circulation 1955; 12: 553-6.
37. 37. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy. N Engl J Med 1975; 292: 1046-50.
38. 38. Penner JA. Managing the hemorrhagic complications of heparin therapy. Hematol Oncol Clin North Am 1994; 7: 1281-9.
39. 39. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-84.
40. 40. Marder VJ. Variations of heparin therapy for thromboembolic disease. Med Clin North Am 1974; 58: 1121-8.
41. 41. Hirsh J. Treatment of venous thrombosis with heparin. In: Kakkar VV, Thomas DP, eds. Heparin: Chemistry and Clinical Usage, New York: Academic Press, 1992: 175-88.
42. 42. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thrombuembolic disease. Chest 1986; 89: S26-35.
43. 43. Moser KM. Pulmonary rhromboembolism. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's Principles of Internal Medicine, 13th ed. New York: McGraw Hill Inc., 1994: 1218-20.
44. 44. Schriever HG, Epstein SE, Mintz MD. Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time. Am J Clin Pathol 1973; 60: 323-9.
45. 45. Wessler S. Current dilemmas in the clinical use of heparin. Fed Proc 1977; 36: 66-9.
46. 46. Conlan MG, Folsom AR, Finch A et al. Antithrombin III: associations with age, race, sex and cardiovascular disease risk factors. Thromb Haemost 1994; 72: 551-6.
47. 47. Whitfield LR, Schentag JJ, Levy GL. Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients. Clin Pharmacol Ther 1982; 32: 503-16.
48. 48. Damus PS, Wallace GA. Immunologic measurement of antithrombin III. Thromb Res 1975; 6: 27-38.
49. 49. Odegard OR, Lie M, Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-94.
50. 50. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors. J Clin Invest 1990; 86: 385-91.
51. 51. Walz DA, Hung G-L. In vivo studies on the binding of heparin and its fractions with platelet factor 4. Semin Thromb Hemost 1985; 11: 40-7.
52. 52. Hirsh J. Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin. In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 283-95.
53. 53. Toffefsen DM. Interaction of glycosaminoglycans with heparin cofactor II. In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 167-75.
54. 54. Wessler S, Gitel SN. Heparin: new concepts relevant to clinical use. Blood 1970; 53: 525-44.
55. 55. Blaisdell FW, Graziano CJ, Effeney DJ. In vivo assessment of anticoagulation. Surgery 1977; 82: 827-39.
56. 56. Blaisdell FW, Graziano CJ. Assessment of clotting by the determination of fibrogen catabolism. Am J Surg 1978; 135: 436-43.
57. 57. Moore FD, Osteen RT, Karp DD et al. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981; 116: 405-7.
58. 58. Solis MM, Ranval TJ, Nix L et al. Is anticoagulation indicated for asymptomatic postoperative calf vein thrombosis? J Vasc Surg 1992; 16: 414-19.
59. 59. Fedullo PF, Hartman MT, Konopka RG et al. Effect of heparin on indium-111 platelet and 1-125 fibrinogen uptake by venous thrombi. Circulation 1983; 68(IIIs): 106.
60. 60. Holm HA, Abildgaard U, Kalvenes S et al. The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays. Acta Med Scand 1984; 216: 287-93.
61. 61. Gravlee GP, Haddon WS, Rothberger HK et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 518-27.
62. 62. Gurewich V. Guidelines for the management of anticoagulant therapy. Semin Thromb Hemost 1976; 2: 176-96.
63. 63. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-40.
64. 64. Weber E, Walter E, Harengerg J. Side effects of heparin: In: Witt I, ed. Heparin: New Biochemical and Medical Aspects. Berlin: Walter de Gruyter, 1983: 241-59.
65. 65. Michel-Meyer S. Treatment of deep vein thrombosis (DVT) with low molecular weight heparins (LMWH). In: Lane DA, Bjork I, Lindahl U, eds. Heparin and Related Polysaccharides. New York: Plenum Press, 1992: 275-81.
66. 66. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-43.
67. 67. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand 1990; 556: 42-50.
68. 68. Deykin D. The risks and benefits of heparin therapy (Editorial). West J Med 1982; 136: 241-2.
69. 69. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-7.
70. 70. Jick H, Slone D, Borda IT, Shapiro S. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279: 284-6.
71. 71. Hull RD, Raskob GE, Rosenbloom D et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4.
72. 72. Kazmier FJ. Anticoagulation. In: Kwaan HC, Bowie EJ, eds. Thrombosis. Philadelphia: WB Saunders, 1982, Chapter 21.
73. 73. Blaisdell FW. Thromboembolic problems, Sect VII. In: Brennan MR, Harken AH, Holcroft JW, Meakins JL, eds. Care of the Surgical Patient. New York: Scientific American, 1992: 2-32.
74. 74. Mant MJ, O'Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG. Hemorrhagic complications of heparin therapy. Lancet 1977; 1: 1133-5.
75. 75. Pitney WR, Pettit JE, Armstrong L. Control of heparin therapy. Br Med J 1970; 2: 139-41.
76. 76. Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 1979; 97: 155-8.
77. 77. Conti S, Daschbach M, Blaisdell FW. A comparison of high-dose versus conventional dose heparin therapy for deep vein thrombosis. Surgery 1982; 92: 972-80.
78. 78. Kashtan JW, Conti S, Blaisdell FW. Heparin therapy for deep venous thrombosis. Am J Surg 1980; 104: 837-42.
79. 79. Hunter G, Carson S, Wong H. Low versus high-dose heparin in the treatment of pulmonary embolism. Vasc Surg 1980; 14: 238-42.
80. 80. Nelson PH, Moser KM, Stoner C, Moser KS. Risk of complications during intravenous heparin therapy. West J Med 1982; 136: 189-97.
81. 81. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987; 82: 703-13.
82. 82. Walker AM, Jick H. Predictors of bleeding during heparin therapy. JAMA 1980; 244: 1209-12.
83. 83. Thomas DP. Heparin and pulmonary embolism. In: Kakkar VV, Thomas DP, eds. Heparin: Chemistry and Clinical Usage. New York: Academic press, 1976: 189-99.
84. 84. Fagher B, Lundh B. Heparin treatment of deep vein thrombosis. Acta Med Scand 1984; 210: 357-61.
85. 85. Engelberg H. Adverse reactions to heparin. In: Engelberg H, ed. Heparin and the Prevention of Atherosclerosis. New York: Wiley-Liss, 1990: 191-7.
86. 86. deTakats G. Heparin: the need for a flexible protocol (Editorial). Am J Surg 1976; 132: 1-3.
87. 87. Adams JG, Humphrey LJ, Zhang X, Silver D. Heparin specific antibodies in patients with heparin induced thrombocytopenia. J Vasc Surg 1995; 21: 247-54.
88. 88. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66: 734-6.
89. 89. Boldt J, Schindler E, Osmer C, Wittstock M, Stertmann WA, Hempelmann G. Influence of different anticoagulation regimens on platelet function during cardiac surgery. Br J Anaesth 1994; 73: 639-44.
90. 90. Ryn-McKenna JV, Ofosu FA, Hirsh J, Buchanan MR. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-9.
91. 91. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994; 58: 799-805.
92. 92. Holmer E, Soderstrom G, Andersson L-O. Effect of heparin in antithrombin III depleted plasma. International Congress on Thrombosis and Haemorrhage 1979; VII, 9.
93. 93. Miller RS, Weatherford DA, Stein D, Crane MM, Stein M. Antithrombin III and trauma patients: factors that determine low levels. J Trauma 1994; 37: 442-5.
94. 94. Blaisdell FW, Steele M, Allen RE. Management of acute arterial ischemia due to embolism and thrombosis. Surgery 1978; 84: 822-34.
95. 95. Quick AJ. On the action of heparin and its relation to thromboplastin. Am J Physiol 1936; 115: 317-33.
96. 96. Fennerty A, Thomas P, Backhouse G et al. Audit of control of heparin treatment. Br Med J Clin Res 1985; 290: 27-8.
97. 97. Gans H, Krivit W. Problems in hemostasis during open heart surgery. IV. On the changes in the blood clotting mechanism during cardiopulmonary bypass surgery. Ann Surg 1961; 155: 353-9.
98. 98. Genton E. Guidelines for heparin therapy. Ann Intern Med 1974; 80: 77-82.
99. 99. Simon TL, Hyers TM, Gaston JP, Harker LA. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978; 39: 111-20.
100. 100. Engelberg H. The clinical use of heparin. Curr Ther Res 1975; 18: 34-44.
101. 101. Wheeler AP, Jaquiss RB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148: 1321-5.
102. 102. Osborn J, MacKenzie R, Shaw A, Perkins H, Hurt R, Gerbode F. Cause and prevention of hemorrhage following extracorporeal circulation. Surg Forum 1955; 6: 96.
103. 103. Perkins HA, Osborn JJ, Gerbode F. The management of abnormal bleeding following extracorporeal circulation. Ann Intern Med 1959; 51: 658-64.
104. 104. Gurewich V. Bleeding low on high dose heparin: clotting time of infinity well tolerated. Acta Chir Scand 1990; 556: 42-50.